Cargando…
Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299771/ https://www.ncbi.nlm.nih.gov/pubmed/34812561 http://dx.doi.org/10.1111/jdv.17836 |
| _version_ | 1784751052810092544 |
|---|---|
| author | Ryan, C. Guenther, L. Foley, P. Weisman, J. Burge, R.T. Gallo, G. See, K. McKean‐Matthews, M. Bertram, C.C. Merola, J.F. |
| author_facet | Ryan, C. Guenther, L. Foley, P. Weisman, J. Burge, R.T. Gallo, G. See, K. McKean‐Matthews, M. Bertram, C.C. Merola, J.F. |
| author_sort | Ryan, C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9299771 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92997712022-07-21 Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial Ryan, C. Guenther, L. Foley, P. Weisman, J. Burge, R.T. Gallo, G. See, K. McKean‐Matthews, M. Bertram, C.C. Merola, J.F. J Eur Acad Dermatol Venereol Letters to the Editor John Wiley and Sons Inc. 2021-12-04 2022-04 /pmc/articles/PMC9299771/ /pubmed/34812561 http://dx.doi.org/10.1111/jdv.17836 Text en © 2021 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| spellingShingle | Letters to the Editor Ryan, C. Guenther, L. Foley, P. Weisman, J. Burge, R.T. Gallo, G. See, K. McKean‐Matthews, M. Bertram, C.C. Merola, J.F. Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial |
| title | Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial |
| title_full | Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial |
| title_fullStr | Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial |
| title_full_unstemmed | Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial |
| title_short | Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial |
| title_sort | ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299771/ https://www.ncbi.nlm.nih.gov/pubmed/34812561 http://dx.doi.org/10.1111/jdv.17836 |
| work_keys_str_mv | AT ryanc ixekizumabprovidespersistentimprovementsinhealthrelatedqualityoflifeandthesexualimpactassociatedwithmoderatetoseveregenitalpsoriasisinadultpatientsduringa52weekrandomisedplacebocontrolledphase3clinicaltrial AT guentherl ixekizumabprovidespersistentimprovementsinhealthrelatedqualityoflifeandthesexualimpactassociatedwithmoderatetoseveregenitalpsoriasisinadultpatientsduringa52weekrandomisedplacebocontrolledphase3clinicaltrial AT foleyp ixekizumabprovidespersistentimprovementsinhealthrelatedqualityoflifeandthesexualimpactassociatedwithmoderatetoseveregenitalpsoriasisinadultpatientsduringa52weekrandomisedplacebocontrolledphase3clinicaltrial AT weismanj ixekizumabprovidespersistentimprovementsinhealthrelatedqualityoflifeandthesexualimpactassociatedwithmoderatetoseveregenitalpsoriasisinadultpatientsduringa52weekrandomisedplacebocontrolledphase3clinicaltrial AT burgert ixekizumabprovidespersistentimprovementsinhealthrelatedqualityoflifeandthesexualimpactassociatedwithmoderatetoseveregenitalpsoriasisinadultpatientsduringa52weekrandomisedplacebocontrolledphase3clinicaltrial AT gallog ixekizumabprovidespersistentimprovementsinhealthrelatedqualityoflifeandthesexualimpactassociatedwithmoderatetoseveregenitalpsoriasisinadultpatientsduringa52weekrandomisedplacebocontrolledphase3clinicaltrial AT seek ixekizumabprovidespersistentimprovementsinhealthrelatedqualityoflifeandthesexualimpactassociatedwithmoderatetoseveregenitalpsoriasisinadultpatientsduringa52weekrandomisedplacebocontrolledphase3clinicaltrial AT mckeanmatthewsm ixekizumabprovidespersistentimprovementsinhealthrelatedqualityoflifeandthesexualimpactassociatedwithmoderatetoseveregenitalpsoriasisinadultpatientsduringa52weekrandomisedplacebocontrolledphase3clinicaltrial AT bertramcc ixekizumabprovidespersistentimprovementsinhealthrelatedqualityoflifeandthesexualimpactassociatedwithmoderatetoseveregenitalpsoriasisinadultpatientsduringa52weekrandomisedplacebocontrolledphase3clinicaltrial AT merolajf ixekizumabprovidespersistentimprovementsinhealthrelatedqualityoflifeandthesexualimpactassociatedwithmoderatetoseveregenitalpsoriasisinadultpatientsduringa52weekrandomisedplacebocontrolledphase3clinicaltrial |